News & Updates

Pirtobrutinib scores a phase III win in BTKi-pretreated CLL/SLL

14 Jan 2025 by

The first phase III trial of pirtobrutinib in haematologic malignancies to readout has demonstrated superiority over investigator's choice in delaying progression in pretreated chronic lymphocytic leukaemia or small lymphocytic lymphoma (CLL/SLL), with results from the BRUIN CLL-321 study first presented at ASH 2024.

Pirtobrutinib scores a phase III win in BTKi-pretreated CLL/SLL

14 Jan 2025

Alectinib trumps crizotinib for ALK+ NSCLC

13 Jan 2025 by

In the 7-year update of the phase III ALESIA trial, alectinib outdoes crizotinib for Asian patients with treatment-naïve, advanced or metastatic ALK+ non-small-cell lung cancer (NSCLC).

Alectinib trumps crizotinib for ALK+ NSCLC

13 Jan 2025

Consolidative stem cell transplant may be skipped for MCL patients with undetectable disease

11 Jan 2025 by

In patients with mantle cell lymphoma (MCL) who have achieved complete remission and undetectable minimal residual disease (MRD) following initial therapy, autologous hematopoietic cell transplantation (auto-HCT) confers no survival advantage when compared with maintenance therapy alone, as shown in the interim results of the phase III ECOG-ACRIN EA4151 trial.

Consolidative stem cell transplant may be skipped for MCL patients with undetectable disease

11 Jan 2025

Active monitoring safe for low-risk ductal carcinoma in situ

10 Jan 2025 by

Among women with low-risk ductal carcinoma in situ, the incidence of invasive cancer in the same breast does not appear to be different between those who have undergone active monitoring and those who have received a surgical procedure, according to the results of COMET trial.

Active monitoring safe for low-risk ductal carcinoma in situ

10 Jan 2025

Blinatumomab plus chemo improves survival in paediatric B-ALL

10 Jan 2025 by

Chemotherapy combined with blinatumomab (blin) delivers significant improvements in disease-free survival (DFS) in children with newly diagnosed National Cancer Institute standard risk (SR) B-cell acute lymphoblastic leukaemia (B-ALL), according to the results of the AALL1731 study presented at ASH 2024.

Blinatumomab plus chemo improves survival in paediatric B-ALL

10 Jan 2025

Tafasitamab plus lenalidomide, rituximab boosts PFS in follicular lymphoma

10 Jan 2025 by

The addition of tafasitamab (tafa) to lenalidomide and rituximab (len+R) significantly improves progression-free survival (PFS) in patients with relapsed or refractory (R/R) follicular lymphoma (FL), as shown in a phase III study presented at ASH 2024. The safety profile of this combination is manageable and consistent with expected toxicities.

Tafasitamab plus lenalidomide, rituximab boosts PFS in follicular lymphoma

10 Jan 2025

Survival benefit with STRIDE for HCC sustained at 5 years

10 Jan 2025 by

The updated exploratory analysis of the phase III HIMALAYA trial demonstrates a significant overall survival (OS) benefit at 5 years with the STRIDE* regimen comprising tremelimumab and durvalumab for patients with unresectable hepatocellular carcinoma (HCC).

Survival benefit with STRIDE for HCC sustained at 5 years

10 Jan 2025

LITESPARK-005 update: Belzutifan benefits East Asians with advanced RCC

10 Jan 2025 by

Treatment with belzutifan improves progression-free survival (PFS) and objective response rate (ORR) in East Asian patients with advanced clear-cell renal cell carcinoma (RCC) compared with everolimus, according to the updated subgroup data of the phase III LITESPARK-005 trial presented at ESMO Asia 2024.

LITESPARK-005 update: Belzutifan benefits East Asians with advanced RCC

10 Jan 2025

Ipsilateral breast cancer recurrence in ‘good-risk’ DCIS reduced with tamoxifen

09 Jan 2025 by

Adjuvant use of tamoxifen is associated with a big drop in the risk of recurrence in the same breast among patients with “good-risk” ductal carcinoma in situ (DCIS) after breast-conserving surgery without radiotherapy.

Ipsilateral breast cancer recurrence in ‘good-risk’ DCIS reduced with tamoxifen

09 Jan 2025

Muscle loss persists in leukaemia patients on nutrition therapy

09 Jan 2025

Muscle or fat-free mass (FFM) decreases in patients with acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS) undergoing intensive chemotherapy despite medical nutrition therapy (MNT), reports a recent study. Fat mass, on the other hand, remains unchanged.

Muscle loss persists in leukaemia patients on nutrition therapy

09 Jan 2025

News & Updates

Filter by Specialty:

Specialty:

Pirtobrutinib scores a phase III win in BTKi-pretreated CLL/SLL

Pirtobrutinib scores a phase III win in BTKi-pretreated CLL/SLL

Alectinib trumps crizotinib for ALK+ NSCLC

Alectinib trumps crizotinib for ALK+ NSCLC

Consolidative stem cell transplant may be skipped for MCL patients with undetectable disease

Consolidative stem cell transplant may be skipped for MCL patients with undetectable disease

Active monitoring safe for low-risk ductal carcinoma in situ

Active monitoring safe for low-risk ductal carcinoma in situ

Blinatumomab plus chemo improves survival in paediatric B-ALL

Blinatumomab plus chemo improves survival in paediatric B-ALL

Tafasitamab plus lenalidomide, rituximab boosts PFS in follicular lymphoma

Tafasitamab plus lenalidomide, rituximab boosts PFS in follicular lymphoma

Survival benefit with STRIDE for HCC sustained at 5 years

Survival benefit with STRIDE for HCC sustained at 5 years

LITESPARK-005 update: Belzutifan benefits East Asians with advanced RCC

LITESPARK-005 update: Belzutifan benefits East Asians with advanced RCC

Ipsilateral breast cancer recurrence in ‘good-risk’ DCIS reduced with tamoxifen

Ipsilateral breast cancer recurrence in ‘good-risk’ DCIS reduced with tamoxifen

Muscle loss persists in leukaemia patients on nutrition therapy

Muscle loss persists in leukaemia patients on nutrition therapy